Pfizer Inc. $PFE Stake Increased by Huntleigh Advisors Inc.

Huntleigh Advisors Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 11.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,135 shares of the biopharmaceutical company’s stock after purchasing an additional 6,588 shares during the period. Huntleigh Advisors Inc.’s holdings in Pfizer were worth $1,579,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. Bessemer Group Inc. increased its stake in shares of Pfizer by 11.1% in the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 13,228 shares during the last quarter. Capital Advisors Inc. OK increased its stake in shares of Pfizer by 1.2% in the first quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after acquiring an additional 17,032 shares during the last quarter. CHURCHILL MANAGEMENT Corp acquired a new position in shares of Pfizer in the first quarter worth $8,283,000. Westbourne Investments Inc. acquired a new position in shares of Pfizer in the first quarter worth $2,411,000. Finally, Bourne Lent Asset Management Inc. increased its stake in shares of Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after acquiring an additional 18,200 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 1.2%

Pfizer stock opened at $24.52 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $139.38 billion, a price-to-earnings ratio of 13.04, a PEG ratio of 0.80 and a beta of 0.55. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.36. The company’s fifty day moving average price is $24.89 and its two-hundred day moving average price is $24.12.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the prior year, the company earned $0.60 earnings per share. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio is 91.49%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Morgan Stanley dropped their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.